Artios Pharma
Cambridge
About Artios Pharma
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. Its clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Pol╬╕) inhibitor ART6043, as well as its preclinical programs, including DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cell’s remaining survival mechanisms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $413.3M
- Funding stage: Late Stage Venture
- Last round: Series D (Nov 2025)
- Website: artiospharma.com
- Phone: +4401223804180
Industries & Categories
Biopharma, Biotechnology, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/artios-pharma-43459 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.